TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) CEO Mary Szela acquired 30,864 shares of the company’s stock in a transaction dated Tuesday, November 17th. The stock was bought at an average cost of $2.31 per share, for a total transaction of $71,295.84. Following the completion of the transaction, the chief executive officer directly owned 1,105,854 shares of the company’s stock, valued at approximately $2,554,522.74. This trade represents a 2.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
TriSalus Life Sciences Stock Performance
NASDAQ TLSI opened at $2.32 on Friday. The company has a debt-to-equity ratio of 47.60, a quick ratio of 3.86 and a current ratio of 4.22. The firm has a 50-day moving average of $3.80 and a 200-day moving average of $4.23. TriSalus Life Sciences, Inc. has a 52-week low of $2.16 and a 52-week high of $7.95.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million. On average, research analysts forecast that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on TLSI shares. HC Wainwright decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 11th. Citigroup reiterated a “buy” rating on shares of TriSalus Life Sciences in a research report on Tuesday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Stifel Nicolaus set a $12.00 price target on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $9.20.
Get Our Latest Stock Report on TriSalus Life Sciences
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth $79,000. New York State Common Retirement Fund acquired a new stake in TriSalus Life Sciences in the third quarter worth about $48,000. Goldman Sachs Group Inc. bought a new position in TriSalus Life Sciences in the 3rd quarter valued at about $497,000. Empowered Funds LLC bought a new position in TriSalus Life Sciences in the 3rd quarter valued at about $275,000. Finally, State Street Corp grew its position in TriSalus Life Sciences by 9.5% in the 3rd quarter. State Street Corp now owns 668,897 shares of the company’s stock valued at $2,883,000 after buying an additional 57,934 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Read More
- Five stocks we like better than TriSalus Life Sciences
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
